[유한 100주년]⑥ 렉라자 잇는 고셔병 신약 YH35995의 가치

The FDA's Orphan Drug Designation for YH35995 marks a pivotal shift for Yuhan Corporation as it transitions from a licensing-focused model to potential direct global commercialization. By targeting the neurological symptoms of Type 3 Gaucher disease—a segment with significant unmet needs—this candidate positions the company to capture high-margin revenue and internalize the entire drug development lifecycle.